Peter Chira

Learn More
OBJECTIVE Epidemiological associations suggest vitamin D may play a role in inflammation and atherosclerosis. Using frozen serum and data from the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we assessed associations between 25-hydroxyvitamin D [25(OH)D] and measures of systemic lupus erythematosus (SLE) disease activity and(More)
OBJECTIVE Epidemiological associations suggest that vitamin D status may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements and other existing data from the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we assessed interactions between serum(More)
Living Profiles is a health media platform in development that aggregates multiple data flows to help teens with special healthcare needs (SHCN), particularly with regard to self-management and independence. A teen-oriented personal health record (PHR) incorporates typical teen behaviors and attitudes about health and wellness, encompasses how teens(More)
Living Profiles is a personal health record (PHR) designed for and by teens with chronic diseases transitioning from the world of pediatric care to the adult system of medical care. It incorporates typical teen behaviors and attitudes about health and wellness while promoting independence, empowerment, and self-care. Our multi-disciplinary team of(More)
BACKGROUND Pain in children with rheumatic conditions such as arthritis is common. However, there is currently no standardized method for the assessment of this pain in children presenting to pediatric rheumatologists. A more consistent and comprehensive approach is needed to effectively assess, treat and monitor pain outcomes in the pediatric rheumatology(More)
Purpose Early aggressive therapy has been shown to result in superior outcomes in adults with RA, but evidence for a similar benefit has not been demonstrated in children with JIA. The objective was to determine if aggressive treatment initiated within the first 12 mos after onset of extended oligoarticular (e-oligo), or RF + or (-) polyarti-cular JIA (poly(More)
  • 1